AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
13.95
14.37
Rango anual
4.71
18.61
Cambio diario
+0.91%
Variación mensual
-8.19%
Variación en los últimos 6 meses
-2.18%
Cambio anual
+188.73%
Cierres anteriores
14.2 2
Open
14.0 1
Mínimo
13.9 5
High
14.3 7
Volumen
666
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 2022202320242025 TTM

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Noticias